Extended treatment tested for rare blistering skin disease
NCT ID NCT05681481
Summary
This study followed adults with moderate-to-severe bullous pemphigoid, a rare autoimmune condition that causes painful skin blisters, to see how safe and effective efgartigimod injections were over a longer period. Participants who completed a previous 36-week study could receive up to 48 more weeks of treatment, with regular check-ups to monitor their skin and symptoms. The goal was to help control the disease while reducing or stopping steroid medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele
Catania, 95123, Italy
-
Azienda Sanitaria Di Firenze
Florence, 50125, Italy
-
Azienda USL Toscana Centro - Ospidale Piero Palagi
Florence, 50122, Italy
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Diagnostic and Consulting Center Aleksandrovska EOOD
Sofia, 1431, Bulgaria
-
Fakultna nemocnica Trnava
Trnava, 91702, Slovakia
-
Fakultni nemocnice Bulovka
Prague, 180 00, Czechia
-
First OC Dermatology
Fountain Valley, California, 92708, United States
-
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, 27100, Italy
-
Fondazione Policlinico Universitario A. Gemelli
Rome, 00168, Italy
-
Guy's and St Thomas' NHS Foundation Trust
London, SE1 9RT, United Kingdom
-
Hokkaido University Hospital
Sapporo, 060-8648, Japan
-
Hospital Of Skin And Venereal Diseases of Thessaloniki
Thessaloniki, 54643, Greece
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Clínico San Cecilio
Granada, 18016, Spain
-
Hospital Universitario Doctor Peset
Valencia, 46017, Spain
-
Hospital of Venereal and Skin Diseases A.Syggros
Athens, 16121, Greece
-
IDI IRCCS - Istituto Dermopatico dell'Immacolata
Roma, 00167, Italy
-
LMU Klinikum der Universität
München, 80337, Germany
-
Medical Dermatology Specialists
Phoenix, Arizona, 85006, United States
-
Miami Dermatology and Laser Institute
Miami, Florida, 33173, United States
-
Ospedale Policlinico San Martino
Genova, 16132, Italy
-
Poliklinika Solmed
Zagreb, 10000, Croatia
-
Premier Specialists
Kogarah, 2217, Australia
-
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
-
Saint Louis University
St Louis, Missouri, 63110, United States
-
Semmelweis Egyetem
Budapest, 1085, Hungary
-
Sheba Medical Center - PPDS
Ramat Gan, 5262100, Israel
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, 400016, China
-
Universitair Medisch Centrum Groningen
Groningen, 9713 GZ, Netherlands
-
Universitatsklinikum Dusseldorf
Düsseldorf, 40225, Germany
-
Universitatsklinikum Schleswig-Holstein
Kiel, 24105, Germany
-
University Clinical Center of Serbia - PPDS
Belgrade, 11000, Serbia
-
University of Michigan Hospital
Ann Arbor, Michigan, 48109, United States
-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Dresden, 01307, Germany
-
Universitätsklinikum Würzburg
Würzburg, 97080, Germany
-
Univerzitna nemocnica Bratislava
Bratislava, 821 06, Slovakia
-
West China Hospital of Sichuan University
Chengdu, 610041, China
-
Wright State Physicians
Fairborn, Ohio, 45324, United States
Conditions
Explore the condition pages connected to this study.